Clinical Trials: BIO Comments to FDA on Draft Guidance on Non-Inferiority Clinical Trials

BIO proposes that the guidance make it more clear which methods are being proposed, as early as possible and consistently throughout the document. We also ask that the document provide additional guidance for the situation where the study has both an active control and a placebo control.